T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C

David E. Kaplan, Kazushi Sugimoto, Fusao Ikeda, Jason Stadanlick, Mary Valiga, Kirti Shetty, K. Rajender Reddy, Kyong Mi Chang

Research output: Contribution to journalArticle

Abstract

Viral genotype and host ethnicity are important predictors of viral clearance during antiviral therapy for chronic hepatitis C virus (HCV) infection. Based on the role of T cells in natural HCV clearance, we hypothesized that T cells may contribute to the genotypic and ethnic difference in treatment outcome. To test this hypothesis, T-cell response to HCV antigens (core, nonstructural NS3/4 and NS5) and control phytohemagglutinin (PHA) was monitored prospectively and was correlated with virological outcome in 41 patients chronically infected with HCV (27 genotype 1, 14 genotype 2 or 3; 19 black persons, 22 white persons) undergoing combined interferon alfa and ribavirin therapy. Interestingly, in patients with genotype 2 or 3 infection, enhanced virological response coincided with a greater T-cell response to HCV NS3/4 antigen at baseline (50% vs. 15%; P = .026) that augmented further during therapy (29% vs. 4%; P = .035) compared with genotype 1-infected patients. However, HCV-specific T-cell response remained weak in genotype 1-infected patients regardless of virological outcome or ethnicity. Furthermore, virological outcome was associated with a suppressed baseline proliferative response to phytohemagglutinin (P <.03) that increased during therapy (P <.003) independent of ethnicity or genotype. In conclusion. HCV-specific T-cell response was associated with HCV genotype but not with therapeutic clearance of HCV infection. The association between treatment outcome and phytohemagglutinin response suggests more global and antigen-nonspecific mechanisms for therapeutic HCV clearance.

Original languageEnglish (US)
Pages (from-to)1365-1375
Number of pages11
JournalHepatology
Volume41
Issue number6
DOIs
StatePublished - Jun 2005
Externally publishedYes

Fingerprint

Chronic Hepatitis C
Hepacivirus
Antiviral Agents
Genotype
T-Lymphocytes
Therapeutics
Phytohemagglutinins
Virus Diseases
Hepatitis C Antigens
Antigens
Ribavirin
Interferon-alpha

ASJC Scopus subject areas

  • Hepatology

Cite this

Kaplan, D. E., Sugimoto, K., Ikeda, F., Stadanlick, J., Valiga, M., Shetty, K., ... Chang, K. M. (2005). T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. Hepatology, 41(6), 1365-1375. https://doi.org/10.1002/hep.20706

T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. / Kaplan, David E.; Sugimoto, Kazushi; Ikeda, Fusao; Stadanlick, Jason; Valiga, Mary; Shetty, Kirti; Reddy, K. Rajender; Chang, Kyong Mi.

In: Hepatology, Vol. 41, No. 6, 06.2005, p. 1365-1375.

Research output: Contribution to journalArticle

Kaplan, DE, Sugimoto, K, Ikeda, F, Stadanlick, J, Valiga, M, Shetty, K, Reddy, KR & Chang, KM 2005, 'T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C', Hepatology, vol. 41, no. 6, pp. 1365-1375. https://doi.org/10.1002/hep.20706
Kaplan DE, Sugimoto K, Ikeda F, Stadanlick J, Valiga M, Shetty K et al. T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. Hepatology. 2005 Jun;41(6):1365-1375. https://doi.org/10.1002/hep.20706
Kaplan, David E. ; Sugimoto, Kazushi ; Ikeda, Fusao ; Stadanlick, Jason ; Valiga, Mary ; Shetty, Kirti ; Reddy, K. Rajender ; Chang, Kyong Mi. / T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. In: Hepatology. 2005 ; Vol. 41, No. 6. pp. 1365-1375.
@article{e67efa0ff93a405eae3497747250f861,
title = "T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C",
abstract = "Viral genotype and host ethnicity are important predictors of viral clearance during antiviral therapy for chronic hepatitis C virus (HCV) infection. Based on the role of T cells in natural HCV clearance, we hypothesized that T cells may contribute to the genotypic and ethnic difference in treatment outcome. To test this hypothesis, T-cell response to HCV antigens (core, nonstructural NS3/4 and NS5) and control phytohemagglutinin (PHA) was monitored prospectively and was correlated with virological outcome in 41 patients chronically infected with HCV (27 genotype 1, 14 genotype 2 or 3; 19 black persons, 22 white persons) undergoing combined interferon alfa and ribavirin therapy. Interestingly, in patients with genotype 2 or 3 infection, enhanced virological response coincided with a greater T-cell response to HCV NS3/4 antigen at baseline (50{\%} vs. 15{\%}; P = .026) that augmented further during therapy (29{\%} vs. 4{\%}; P = .035) compared with genotype 1-infected patients. However, HCV-specific T-cell response remained weak in genotype 1-infected patients regardless of virological outcome or ethnicity. Furthermore, virological outcome was associated with a suppressed baseline proliferative response to phytohemagglutinin (P <.03) that increased during therapy (P <.003) independent of ethnicity or genotype. In conclusion. HCV-specific T-cell response was associated with HCV genotype but not with therapeutic clearance of HCV infection. The association between treatment outcome and phytohemagglutinin response suggests more global and antigen-nonspecific mechanisms for therapeutic HCV clearance.",
author = "Kaplan, {David E.} and Kazushi Sugimoto and Fusao Ikeda and Jason Stadanlick and Mary Valiga and Kirti Shetty and Reddy, {K. Rajender} and Chang, {Kyong Mi}",
year = "2005",
month = "6",
doi = "10.1002/hep.20706",
language = "English (US)",
volume = "41",
pages = "1365--1375",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C

AU - Kaplan, David E.

AU - Sugimoto, Kazushi

AU - Ikeda, Fusao

AU - Stadanlick, Jason

AU - Valiga, Mary

AU - Shetty, Kirti

AU - Reddy, K. Rajender

AU - Chang, Kyong Mi

PY - 2005/6

Y1 - 2005/6

N2 - Viral genotype and host ethnicity are important predictors of viral clearance during antiviral therapy for chronic hepatitis C virus (HCV) infection. Based on the role of T cells in natural HCV clearance, we hypothesized that T cells may contribute to the genotypic and ethnic difference in treatment outcome. To test this hypothesis, T-cell response to HCV antigens (core, nonstructural NS3/4 and NS5) and control phytohemagglutinin (PHA) was monitored prospectively and was correlated with virological outcome in 41 patients chronically infected with HCV (27 genotype 1, 14 genotype 2 or 3; 19 black persons, 22 white persons) undergoing combined interferon alfa and ribavirin therapy. Interestingly, in patients with genotype 2 or 3 infection, enhanced virological response coincided with a greater T-cell response to HCV NS3/4 antigen at baseline (50% vs. 15%; P = .026) that augmented further during therapy (29% vs. 4%; P = .035) compared with genotype 1-infected patients. However, HCV-specific T-cell response remained weak in genotype 1-infected patients regardless of virological outcome or ethnicity. Furthermore, virological outcome was associated with a suppressed baseline proliferative response to phytohemagglutinin (P <.03) that increased during therapy (P <.003) independent of ethnicity or genotype. In conclusion. HCV-specific T-cell response was associated with HCV genotype but not with therapeutic clearance of HCV infection. The association between treatment outcome and phytohemagglutinin response suggests more global and antigen-nonspecific mechanisms for therapeutic HCV clearance.

AB - Viral genotype and host ethnicity are important predictors of viral clearance during antiviral therapy for chronic hepatitis C virus (HCV) infection. Based on the role of T cells in natural HCV clearance, we hypothesized that T cells may contribute to the genotypic and ethnic difference in treatment outcome. To test this hypothesis, T-cell response to HCV antigens (core, nonstructural NS3/4 and NS5) and control phytohemagglutinin (PHA) was monitored prospectively and was correlated with virological outcome in 41 patients chronically infected with HCV (27 genotype 1, 14 genotype 2 or 3; 19 black persons, 22 white persons) undergoing combined interferon alfa and ribavirin therapy. Interestingly, in patients with genotype 2 or 3 infection, enhanced virological response coincided with a greater T-cell response to HCV NS3/4 antigen at baseline (50% vs. 15%; P = .026) that augmented further during therapy (29% vs. 4%; P = .035) compared with genotype 1-infected patients. However, HCV-specific T-cell response remained weak in genotype 1-infected patients regardless of virological outcome or ethnicity. Furthermore, virological outcome was associated with a suppressed baseline proliferative response to phytohemagglutinin (P <.03) that increased during therapy (P <.003) independent of ethnicity or genotype. In conclusion. HCV-specific T-cell response was associated with HCV genotype but not with therapeutic clearance of HCV infection. The association between treatment outcome and phytohemagglutinin response suggests more global and antigen-nonspecific mechanisms for therapeutic HCV clearance.

UR - http://www.scopus.com/inward/record.url?scp=20044395103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044395103&partnerID=8YFLogxK

U2 - 10.1002/hep.20706

DO - 10.1002/hep.20706

M3 - Article

C2 - 15915458

AN - SCOPUS:20044395103

VL - 41

SP - 1365

EP - 1375

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 6

ER -